tetano
Editor, Senior Moderator
Emerg Microbes Infect
. 2021 Jan 5;1-28.
doi: 10.1080/22221751.2021.1872353. Online ahead of print.
The interplay between emerging human coronavirus infections and autophagy
Zhenyu Zhao[SUP] 1 [/SUP], Kefeng Lu[SUP] 2 [/SUP], Binli Mao[SUP] 1 [/SUP], Shi Liu[SUP] 3 [/SUP], Mirko Trilling[SUP] 4 [/SUP], Ailong Huang[SUP] 1 [/SUP], Mengji Lu[SUP] 4 [/SUP], Yong Lin[SUP] 1 [/SUP]
Affiliations
Abstract
Following outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2002 and 2012, respectively, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic emerging human coronavirus (hCoV). SARS-CoV-2 is currently causing the global coronavirus disease 2019 (COVID-19) pandemic. CoV infections in target cells may stimulate the formation of numerous double-membrane autophagosomes and induce autophagy. Several studies provided evidence that hCoV infections are closely related to various cellular aspects associated with autophagy. Autophagy may even promote hCoV infection and replication. However, so far it is unclear how hCoV infections induce autophagy and whether the autophagic machinery is necessary for viral propagation. Here, we summarize the most recent advances concerning the mutual interplay between the autophagic machinery and the three emerging hCoVs, SARS-CoV, MERS-CoV, and SARS-CoV-2 and the model system mouse hepatitis virus. We also discuss the applicability of approved and well-tolerated drugs targeting autophagy as potential treatment against COVID-19.
Keywords: Autophagy; MERS-CoV; MHV; SARS-CoV; SARS-CoV-2; coronavirus.
. 2021 Jan 5;1-28.
doi: 10.1080/22221751.2021.1872353. Online ahead of print.
The interplay between emerging human coronavirus infections and autophagy
Zhenyu Zhao[SUP] 1 [/SUP], Kefeng Lu[SUP] 2 [/SUP], Binli Mao[SUP] 1 [/SUP], Shi Liu[SUP] 3 [/SUP], Mirko Trilling[SUP] 4 [/SUP], Ailong Huang[SUP] 1 [/SUP], Mengji Lu[SUP] 4 [/SUP], Yong Lin[SUP] 1 [/SUP]
Affiliations
- PMID: 33399028
- DOI: 10.1080/22221751.2021.1872353
Abstract
Following outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2002 and 2012, respectively, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third highly pathogenic emerging human coronavirus (hCoV). SARS-CoV-2 is currently causing the global coronavirus disease 2019 (COVID-19) pandemic. CoV infections in target cells may stimulate the formation of numerous double-membrane autophagosomes and induce autophagy. Several studies provided evidence that hCoV infections are closely related to various cellular aspects associated with autophagy. Autophagy may even promote hCoV infection and replication. However, so far it is unclear how hCoV infections induce autophagy and whether the autophagic machinery is necessary for viral propagation. Here, we summarize the most recent advances concerning the mutual interplay between the autophagic machinery and the three emerging hCoVs, SARS-CoV, MERS-CoV, and SARS-CoV-2 and the model system mouse hepatitis virus. We also discuss the applicability of approved and well-tolerated drugs targeting autophagy as potential treatment against COVID-19.
Keywords: Autophagy; MERS-CoV; MHV; SARS-CoV; SARS-CoV-2; coronavirus.